Cancer (Future parent protocols may include other cancer that are not included in this section)
Conditions
Brief summary
N/A (Not Applicable)
Detailed description
Incidence and severity of serious adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0, Incidence and severity of adverse events of special interest, with severity determined according to NCI CTCAE, v4.0, Time from randomization or treatment initiation (as indicated in parent study protocol) to death due to any cause (For patients from Impower 133 only)
Interventions
DRUGTecentriq 1 200 mg concentrate for solution for infusion
Sponsors
F. Hoffmann-La Roche AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N/A (Not Applicable) | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of serious adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v4.0, Incidence and severity of adverse events of special interest, with severity determined according to NCI CTCAE, v4.0, Time from randomization or treatment initiation (as indicated in parent study protocol) to death due to any cause (For patients from Impower 133 only) | — |
Countries
Austria, Czechia, France, Hungary, Poland, Spain
Outcome results
None listed